1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.81%
Revenue growth under 50% of CRON.TO's 15.38%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
23.28%
Gross profit growth under 50% of CRON.TO's 68.22%. Michael Burry would be concerned about a severe competitive disadvantage.
119.76%
Positive EBIT growth while CRON.TO is negative. John Neff might see a substantial edge in operational management.
119.76%
Operating income growth above 1.5x CRON.TO's 29.45%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-0.34%
Negative net income growth while CRON.TO stands at 30.89%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
5.93%
EPS growth under 50% of CRON.TO's 22.22%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
7.76%
Diluted EPS growth under 50% of CRON.TO's 25.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-73.67%
Negative OCF growth while CRON.TO is at 26.90%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-24.62%
Negative FCF growth while CRON.TO is at 14.45%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
729.33%
3Y revenue/share CAGR similar to CRON.TO's 685.95%. Walter Schloss would assume both companies experience comparable short-term cycles.
-5193.14%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-372.30%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-681.49%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
1634.96%
Net income/share CAGR 1.25-1.5x CRON.TO's 1369.28%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
2589.28%
5Y net income/share CAGR above 1.5x CRON.TO's 1369.28%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
428.42%
Below 50% of CRON.TO's 4412.15%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
6077.40%
10Y equity/share CAGR above 1.5x CRON.TO's 2453.20%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
14361.42%
5Y equity/share CAGR above 1.5x CRON.TO's 2453.20%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
589.54%
Below 50% of CRON.TO's 1524.19%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
34.59%
Our AR growth while CRON.TO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
24.96%
Inventory growth well above CRON.TO's 13.34%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
0.90%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
2.53%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
-1.79%
We’re deleveraging while CRON.TO stands at 47.90%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
135.68%
We increase R&D while CRON.TO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
2.34%
SG&A declining or stable vs. CRON.TO's 6.38%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.